sentence
stringlengths 27
1.01k
| drug1
stringlengths 2
46
| drug2
stringlengths 2
63
| relation
stringclasses 5
values | source_file
stringclasses 566
values | sentence_id
stringlengths 17
21
| pair_id
stringlengths 20
26
|
|---|---|---|---|---|---|---|
Isoflurane, enflurane, and halothane decrease the ED50 of NUROMAX by 30% to 45%.
|
enflurane
|
NUROMAX
|
MECHANISM
|
Doxacurium chloride_ddi.xml
|
DDI-DrugBank.d267.s3
|
DDI-DrugBank.d267.s3.p4
|
Potassium Supplements and Potassium-Sparing Diuretics: Fosinopril sodium can attenuate potassium loss caused by thiazide diuretics.
|
Potassium
|
Fosinopril sodium
|
NONE
|
Fosinopril_ddi.xml
|
DDI-DrugBank.d176.s3
|
DDI-DrugBank.d176.s3.p1
|
Because prostaglandins play an important role in hemostasis, and NSAIDs affect platelet function as well, concurrent therapy with all NSAIDs, including diclofenac, and warfarin requires close monitoring of patients to be certain that no change in their anticoagulant dosage is required.
|
diclofenac
|
warfarin
|
ADVISE
|
Diclofenac_ddi.xml
|
DDI-DrugBank.d249.s2
|
DDI-DrugBank.d249.s2.p7
|
Increasing the indinavir dose to 1000 mg every 8 hours does not compensate for the increased indinavir metabolism due to efavirenz.
|
indinavir
|
indinavir
|
NONE
|
Indinavir_ddi.xml
|
DDI-DrugBank.d97.s41
|
DDI-DrugBank.d97.s41.p0
|
Anticonvulsants (carbamazepine, felbamate, phenobarbital, phenytoin, topiramate): Increase the metabolism of ethinyl estradiol and/or some progestins, leading to possible decrease in contraceptive effectiveness.
|
felbamate
|
progestins
|
MECHANISM
|
Ethynodiol Diacetate_ddi.xml
|
DDI-DrugBank.d485.s12
|
DDI-DrugBank.d485.s12.p17
|
the doses of naloxone required to antagonize the effects of (-)-NANM were more than 100 times higher than those required to antagonize the effects of morphine.
|
naloxone
|
(-)-NANM
|
EFFECT
|
3968644.xml
|
DDI-MedLine.d30.s9
|
DDI-MedLine.d30.s9.p0
|
Flurbiprofen pretreatment attenuated the hypotensive effect of a single dose of propranolol but not atenolol.
|
Flurbiprofen
|
propranolol
|
EFFECT
|
Flurbiprofen_ddi.xml
|
DDI-DrugBank.d529.s8
|
DDI-DrugBank.d529.s8.p0
|
Oral contraceptives: Aprepitant, when given once daily for 14 days as a 100-mg capsule with an oral contraceptive containing 35 mcg of ethinyl estradiol and 1 mg of norethindrone, decreased the AUC of ethinyl estradiol by 43%, and decreased the AUC of norethindrone by 8%;
|
Aprepitant
|
contraceptive
|
NONE
|
Aprepitant_ddi.xml
|
DDI-DrugBank.d382.s19
|
DDI-DrugBank.d382.s19.p6
|
These results suggest that the analgesic effect of STADOL NS may be diminished when it is administered shortly after sumatriptan nasal spray, but by 30 minutes any such reduction in effect should be minimal.
|
STADOL NS
|
sumatriptan
|
EFFECT
|
Butorphanol_ddi.xml
|
DDI-DrugBank.d246.s7
|
DDI-DrugBank.d246.s7.p0
|
In a Phase I trial using escalating doses of TAXOL (110-200 mg/m2) and cisplatin (50 or 75 mg/m2) given as sequential infusions, myelosuppression was more profound when TAXOL was given after cisplatin than with the alternate sequence (ie, TAXOL before cisplatin).
|
TAXOL
|
cisplatin
|
EFFECT
|
Paclitaxel_ddi.xml
|
DDI-DrugBank.d288.s0
|
DDI-DrugBank.d288.s0.p9
|
Patients receiving concomitant lovastatin and erythromycin should be carefully monitored;
|
lovastatin
|
erythromycin
|
ADVISE
|
Erythromycin_ddi.xml
|
DDI-DrugBank.d397.s15
|
DDI-DrugBank.d397.s15.p0
|
Curariform muscle relaxants (eg, tubocurarine) and other drugs, including ether, succinylcholine, gallamine, decamethonium and sodium citrate, potentiate the neuromuscular blocking effect and should be used with extreme caution in patients being treated with Coly-Mycin M Parenteral.
|
Curariform muscle relaxants
|
decamethonium
|
NONE
|
Colistimethate_ddi.xml
|
DDI-DrugBank.d250.s2
|
DDI-DrugBank.d250.s2.p3
|
Anticholinergic drugs may antagonize the effects of the drugs that alter gastrointestinal motility, such as metoclopramide.
|
Anticholinergic drugs
|
metoclopramide
|
MECHANISM
|
Dicyclomine_ddi.xml
|
DDI-DrugBank.d543.s6
|
DDI-DrugBank.d543.s6.p0
|
Although clinical studies have not been performed, based on the involvement of the cytochrome P-450 3A family in clonazepam metabolism, inhibitors of this enzyme system, notably oral antifungal agents, should be used cautiously in patients receiving clonazepam.
|
antifungal agents
|
clonazepam
|
ADVISE
|
Clonazepam_ddi.xml
|
DDI-DrugBank.d333.s6
|
DDI-DrugBank.d333.s6.p2
|
There have been reports of interactions of erythromycin with carbamazepine, cyclosporine, tacrolimus, hexobarbital, phenytoin, alfentanil, cisapride, disopyramide, lovastatin, bromocriptine, valproate, terfenadine, and astemizole.
|
alfentanil
|
bromocriptine
|
NONE
|
Erythromycin_ddi.xml
|
DDI-DrugBank.d397.s8
|
DDI-DrugBank.d397.s8.p66
|
H-2 Antagonists: In studies with human volunteers, co-administration of cimetidine or ranitidine with ibuprofen had no substantive effect on ibuprofen serum concentrations.
|
ibuprofen
|
ibuprofen
|
NONE
|
Ibuprofen_ddi.xml
|
DDI-DrugBank.d415.s8
|
DDI-DrugBank.d415.s8.p5
|
Inhibitors Of Endogenous Prostaglandin Synthesis It has been reported that indomethacin may reduce the antihypertensive effect of captopril, especially in cases of low renin hypertension.
|
indomethacin
|
captopril
|
EFFECT
|
Captopril_ddi.xml
|
DDI-DrugBank.d175.s16
|
DDI-DrugBank.d175.s16.p0
|
Methotrexate: Concomitant administration of methotrexate and some NSAIDs has been reported to reduce the clearance of methotrexate, enhancing the toxicity of methotrexate.
|
Methotrexate
|
methotrexate
|
NONE
|
Ketorolac_ddi.xml
|
DDI-DrugBank.d3.s13
|
DDI-DrugBank.d3.s13.p3
|
When carbamazepine is added to aripiprazole therapy, aripiprazole dose should be doubled.
|
carbamazepine
|
aripiprazole
|
NONE
|
Aripiprazole_ddi.xml
|
DDI-DrugBank.d509.s20
|
DDI-DrugBank.d509.s20.p1
|
- a diuretic (water pill) such as hydrochlorothiazide (HCTZ, Hydrodiuril), chlorothiazide (Diuril), and others;
|
diuretic
|
Hydrodiuril
|
NONE
|
Glimepiride_ddi.xml
|
DDI-DrugBank.d521.s6
|
DDI-DrugBank.d521.s6.p2
|
Administration of quinolones with antacids containing aluminum, magnesium, or calcium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as VIDEX (didanosine) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones, resulting in systemic concentrations considerably lower than desired.
|
quinolones
|
sucralfate
|
MECHANISM
|
Grepafloxacin_ddi.xml
|
DDI-DrugBank.d78.s1
|
DDI-DrugBank.d78.s1.p4
|
Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.
|
amiodarone
|
heparin
|
NONE
|
Levothyroxine_ddi.xml
|
DDI-DrugBank.d411.s4
|
DDI-DrugBank.d411.s4.p78
|
Agents Increasing Serum Potassium: Enalapril and enalapril IV attenuate potassium loss caused by thiazide-type diuretics.
|
enalapril
|
thiazide-type diuretics
|
EFFECT
|
Enalapril_ddi.xml
|
DDI-DrugBank.d107.s12
|
DDI-DrugBank.d107.s12.p2
|
Phenytoin: If acitretin is given concurrently with phenytoin, the protein binding of phenytoin may be reduced.
|
acitretin
|
phenytoin
|
MECHANISM
|
Acitretin_ddi.xml
|
DDI-DrugBank.d353.s10
|
DDI-DrugBank.d353.s10.p3
|
Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol: Flupenthixol and Ethanol cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of Tricyclic antidepressants
|
MAOI
|
Ethanol
|
NONE
|
Flupenthixol_ddi.xml
|
DDI-DrugBank.d13.s0
|
DDI-DrugBank.d13.s0.p32
|
Nifedipine did not alter the plasma levels of Vardenafil when taken in combination.
|
Nifedipine
|
Vardenafil
|
NONE
|
Vardenafil_ddi.xml
|
DDI-DrugBank.d198.s26
|
DDI-DrugBank.d198.s26.p0
|
The actions of the benzodiazepines may be potentiated by barbiturates, narcotics, phenothiazines, monoamine oxidase inhibitors or other antidepressants.
|
benzodiazepines
|
phenothiazines
|
EFFECT
|
Clorazepate_ddi.xml
|
DDI-DrugBank.d335.s3
|
DDI-DrugBank.d335.s3.p2
|
The benzodiazepines, including alprazolam, produce additive CNS depressant effects when co-administered with other psychotropic medications, anticonvulsants, antihistaminics, ethanol, and other drugs which themselves produce CNS depression.
|
anticonvulsants
|
ethanol
|
NONE
|
Alprazolam_ddi.xml
|
DDI-DrugBank.d131.s0
|
DDI-DrugBank.d131.s0.p13
|
Fenfluramine may increase slightly the effect of antihypertensive drugs, e.g., guanethidine, methyldopa, reserpine.
|
antihypertensive drugs
|
reserpine
|
NONE
|
Fenfluramine_ddi.xml
|
DDI-DrugBank.d104.s0
|
DDI-DrugBank.d104.s0.p6
|
The anticoagulant effect of heparin is enhanced by concurrent treatment with antithrombin III (human) in patients with hereditary antithrombin III deficiency.
|
heparin
|
antithrombin III
|
EFFECT
|
Heparin_ddi.xml
|
DDI-DrugBank.d488.s3
|
DDI-DrugBank.d488.s3.p0
|
Valproic acid diminished binding of phenobarbital by a net change of 9.9% (percentage increase in FDF, 21.2%) at 1732 micromol/L.
|
Valproic acid
|
phenobarbital
|
MECHANISM
|
11206047.xml
|
DDI-MedLine.d111.s12
|
DDI-MedLine.d111.s12.p0
|
If labetalol HCl is used with nitroglycerin in patients with angina pectoris, additional antihypertensive effects may occur.
|
labetalol HCl
|
nitroglycerin
|
EFFECT
|
Labetalol_ddi.xml
|
DDI-DrugBank.d412.s10
|
DDI-DrugBank.d412.s10.p0
|
Sympathomimetic amines may reduce the antihypertensive effects of reserpine, veratrum alkaloids, methyldopa and mecamylamine.
|
veratrum alkaloids
|
mecamylamine
|
NONE
|
Carbinoxamine_ddi.xml
|
DDI-DrugBank.d389.s2
|
DDI-DrugBank.d389.s2.p8
|
Central nervous system depressant (CNS) drugs including alcohol, antidepressants, antihistamines, antipsychotics, blood pressure medications (reserpine, methyldopa, beta-blockers), motion sickness medications, muscle relaxants, narcotics, sedatives, sleeping pills and tranquilizers
|
antihistamines
|
reserpine
|
NONE
|
Citalopram_ddi.xml
|
DDI-DrugBank.d472.s0
|
DDI-DrugBank.d472.s0.p31
|
Certain drugs including thiazides, corticosteroids, thyroid products, and sympathomimetics may reduce the hypoglycemic action of Starlix and other oral antidiabetic drugs.
|
corticosteroids
|
Starlix
|
EFFECT
|
Nateglinide_ddi.xml
|
DDI-DrugBank.d460.s15
|
DDI-DrugBank.d460.s15.p7
|
During clinical trials, iloprost was used concurrently with anticoagulants, diuretics, cardiac glycosides, calcium channel blockers, analgesics, antipyretics, nonsteroidal antiinflammatories, corticosteroids, and other medications.
|
iloprost
|
diuretics
|
NONE
|
Iloprost_ddi.xml
|
DDI-DrugBank.d549.s3
|
DDI-DrugBank.d549.s3.p1
|
Response to sympathomimetic agents may be enhanced by colchicine.
|
sympathomimetic agents
|
colchicine
|
EFFECT
|
Colchicine_ddi.xml
|
DDI-DrugBank.d146.s3
|
DDI-DrugBank.d146.s3.p0
|
Antibiotics: In vitro and/or in vivo data show that clarithromycin, erythromycin, and troleandomycin markedly inhibit the metabolism of cisapride, which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.
|
troleandomycin
|
cisapride
|
MECHANISM
|
Cisapride_ddi.xml
|
DDI-DrugBank.d237.s2
|
DDI-DrugBank.d237.s2.p12
|
Because changes in glucose concentrations with valdecoxib coadministration were within the normal variability and individual glucose concentrations were above or near 70 mg/dL, dose adjustment for glyburide (5 mg QD and 10 mg BID) with valdecoxib coadministration (up to 40 mg QD) is not indicated.
|
glyburide
|
valdecoxib
|
ADVISE
|
Valdecoxib_ddi.xml
|
DDI-DrugBank.d328.s35
|
DDI-DrugBank.d328.s35.p2
|
Cimetidine treatment should be stopped during treatment with ELLENCE.
|
Cimetidine
|
ELLENCE
|
ADVISE
|
Epirubicin_ddi.xml
|
DDI-DrugBank.d428.s11
|
DDI-DrugBank.d428.s11.p0
|
While no in vivo drug-drug interaction studies were conducted between estazolam and inducers of CYP3A, compounds that are potent CYP3A inducers (such as carbamazepine, phenytoin, rifampin, and barbiturates) would be expected to decrease estazolam concentrations.
|
estazolam
|
rifampin
|
MECHANISM
|
Estazolam_ddi.xml
|
DDI-DrugBank.d338.s4
|
DDI-DrugBank.d338.s4.p2
|
Both the magnitude and duration of central nervous system and cardiovascular effects may be enhanced when ALFENTA is administered in combination with other CNS depressants such as barbiturates, tranquilizers, opioids, or inhalation general anesthetics.
|
ALFENTA
|
tranquilizers
|
EFFECT
|
Alfentanil_ddi.xml
|
DDI-DrugBank.d8.s0
|
DDI-DrugBank.d8.s0.p2
|
Multivitamins, or other products containing iron or zinc, antacids or sucralfate should not be administered concomitantly with, or within 2 hours of, the administration of norfloxacin, because they may interfere with absorption resulting in lower serum and urine levels of norfloxacin.
|
zinc
|
norfloxacin
|
ADVISE
|
Norfloxacin_ddi.xml
|
DDI-DrugBank.d217.s11
|
DDI-DrugBank.d217.s11.p13
|
- Perhexiline hydrogen maleate or MAO-inhibitors (with hepatotoxic potential) must not be administered together with Bezalip or Bezalip retard.
|
Bezalip
|
Bezalip retard
|
NONE
|
Bezafibrate_ddi.xml
|
DDI-DrugBank.d291.s11
|
DDI-DrugBank.d291.s11.p5
|
The plasma concentration of imipramine may increase when the drug is given concomitantly with hepatic enzyme inhibitors (e.g., cimetidine, fluoxetine) and decrease by concomitant administration of hepatic enzyme inducers (e.g., barbiturates, phenytoin), and adjustment of the dosage of imipramine may therefore be necessary.
|
imipramine
|
phenytoin
|
MECHANISM
|
Imipramine_ddi.xml
|
DDI-DrugBank.d77.s5
|
DDI-DrugBank.d77.s5.p3
|
Coingestion of acetaminophen with theophylline, phenobarbital with acetaminophen, and valproic acid with phenobarbital at high to toxic concentrations decreases the binding of the target drug.
|
valproic acid
|
phenobarbital
|
EFFECT
|
11206047.xml
|
DDI-MedLine.d111.s14
|
DDI-MedLine.d111.s14.p14
|
Caution should be used when administering or taking TARCEVA with ketoconazole and other strong CYP3A4 inhibitors such as, but not limited to, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, troleandomycin (TAO), and voriconazole .
|
TARCEVA
|
ketoconazole
|
ADVISE
|
Erlotinib_ddi.xml
|
DDI-DrugBank.d456.s1
|
DDI-DrugBank.d456.s1.p0
|
Probenecid: Probenecid interferes with renal tubular secretion of ciprofloxacin and produces an increase in the level of ciprofloxacin in serum.
|
Probenecid
|
ciprofloxacin
|
MECHANISM
|
Ciprofloxacin_ddi.xml
|
DDI-DrugBank.d123.s15
|
DDI-DrugBank.d123.s15.p4
|
Phenytoin/Phenobarbital: The coadministration of phenytoin or phenobarbital will not affect plasma concentrations of vitamin D, but may reduce endogenous plasma levels of calcitriol/ergocalcitriol by accelerating metabolism.
|
Phenytoin
|
phenobarbital
|
NONE
|
Cholecalciferol_ddi.xml
|
DDI-DrugBank.d404.s2
|
DDI-DrugBank.d404.s2.p2
|
Magnesium- and/or aluminum-containing antacids, products containing ferrous sulfate (iron), multivitamin preparations containing zinc or other metal cations, or Videx (didanosine) chewable/buffered tablets or the pediatric powder for oral solution should not be taken within 3 hours before or 2 hours after FACTIVE.
|
ferrous sulfate
|
FACTIVE
|
ADVISE
|
Gemifloxacin_ddi.xml
|
DDI-DrugBank.d347.s7
|
DDI-DrugBank.d347.s7.p29
|
poor metabolizers of debrisoquin: Interactions of carvedilol with strong inhibitors of CYP2D6 (such as quinidine, fluoxetine, paroxetine, and propafenone) have not been studied, but these drugs would be expected to increase blood levels of the R(+) enantiomer of carvedilol .
|
paroxetine
|
carvedilol
|
EFFECT
|
Carvedilol_ddi.xml
|
DDI-DrugBank.d269.s1
|
DDI-DrugBank.d269.s1.p19
|
Caffeine: Enoxacin is a potent inhibitor of the cytochrome P-450 isozymes responsible for the metabolism of methylxanthines.
|
Enoxacin
|
methylxanthines
|
MECHANISM
|
Enoxacin_ddi.xml
|
DDI-DrugBank.d395.s2
|
DDI-DrugBank.d395.s2.p2
|
Alcohol: In post-marketing experience, there have been rare reports of adverse neuropsychiatric events or reduced alcohol tolerance in patients who were drinking alcohol during treatment with WELLBUTRIN.
|
alcohol
|
WELLBUTRIN
|
EFFECT
|
Bupropion_ddi.xml
|
DDI-DrugBank.d5.s25
|
DDI-DrugBank.d5.s25.p5
|
therefore, plasma concentrations of phenytoin should also be monitored when it is given concurrently with Itraconazole.
|
phenytoin
|
Itraconazole
|
ADVISE
|
Itraconazole_ddi.xml
|
DDI-DrugBank.d165.s21
|
DDI-DrugBank.d165.s21.p0
|
In addition, neuromuscular blocking action is enhanced by general anesthetics, local anesthetics like lidocaine, procaine, beta-blockers, metaclopramide, lithium carbonate, and terbutaline.
|
beta-blockers
|
lithium carbonate
|
NONE
|
Decamethonium_ddi.xml
|
DDI-DrugBank.d167.s2
|
DDI-DrugBank.d167.s2.p23
|
Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
|
anticonvulsants
|
Atromid-S
|
NONE
|
Etonogestrel_ddi.xml
|
DDI-DrugBank.d484.s0
|
DDI-DrugBank.d484.s0.p262
|
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;
|
dapsone
|
pimozide
|
NONE
|
Saquinavir_ddi.xml
|
DDI-DrugBank.d124.s26
|
DDI-DrugBank.d124.s26.p24
|
Drug Interactions: The central anticholinergic syndrome can occur when anticholinergic agents such as AKINETON are administered concomitantly with drugs that have secondary anticholinergic actions, e.g., certain narcotic analgesics such as meperidine, the phenothiazines and other antipsychotics, tricyclic antidepressants, certain antiarrhythmics such as the quinidine salts, and antihistamines.
|
anticholinergic
|
quinidine
|
EFFECT
|
Biperiden_ddi.xml
|
DDI-DrugBank.d401.s0
|
DDI-DrugBank.d401.s0.p7
|
Drugs that have been reported to diminish oral anticoagulant response, ie, decreased prothrom-bin time response, in man significantly include: adrenocortical steroids;alcohol*;antacids;antihistamines;barbiturates;carbamazepine;chloral hydrate*;chlordiazepoxide;cholestyramine;diet high in vitamin K;diuretics*;ethchlorvynol;glutethimide;griseofulvin;haloperidol;meprobamate;oral contraceptives;paraldehyde;primidone;ranitidine*;rifampin;unreliable prothrombin time determinations;vitamin C;warfarin sodium under-dosage.
|
carbamazepine
|
rifampin
|
NONE
|
Anisindione_ddi.xml
|
DDI-DrugBank.d64.s29
|
DDI-DrugBank.d64.s29.p137
|
Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.
|
b-adrenergic blocking agents
|
chloral hydrate
|
NONE
|
Levothyroxine_ddi.xml
|
DDI-DrugBank.d411.s4
|
DDI-DrugBank.d411.s4.p237
|
Lincomycin has been shown to have neuromuscular blocking properties that may enhance the action of other neuromuscular blocking agents.
|
Lincomycin
|
neuromuscular blocking agents
|
EFFECT
|
Lincomycin_ddi.xml
|
DDI-DrugBank.d130.s0
|
DDI-DrugBank.d130.s0.p0
|
Aspirin: In normal volunteers, a small decrease in diflunisal levels was observed when multiple doses of diflunisal and aspirin were administered concomitantly.
|
diflunisal
|
aspirin
|
MECHANISM
|
Diflunisal_ddi.xml
|
DDI-DrugBank.d132.s25
|
DDI-DrugBank.d132.s25.p5
|
Although deferasirox has a lower affinity for aluminum than for iron, Exjade should not be taken with aluminum-containing antacid preparations.
|
Exjade
|
aluminum
|
ADVISE
|
Deferasirox_ddi.xml
|
DDI-DrugBank.d84.s1
|
DDI-DrugBank.d84.s1.p12
|
Agents that are CYP inducers that have been found, or are expected, to decrease plasma levels of EQUETROTM are the following: Cisplatin, doxorubicin HCL, felbamate, rifampin, phenobarbital, Phenytoin(2), primidone, methsuximide, and theophylline Thus, if a patient has been titrated to a stable dosage on EQUETROTM, and then begins a course of treatment with one of these CYP3A4 inducers, it is reasonable to expect that a dose increase for EQUETROTM may be necessary.
|
rifampin
|
Phenytoin
|
NONE
|
Carbamazepine_ddi.xml
|
DDI-DrugBank.d94.s8
|
DDI-DrugBank.d94.s8.p39
|
and Videx , (Didanosine), chewable/buffered tablets or the pediatric powder for oral solution may substantially interfere with the absorption of quinolones, resulting in systemic levels considerably lower than desired.
|
Didanosine
|
quinolones
|
MECHANISM
|
Nalidixic Acid_ddi.xml
|
DDI-DrugBank.d427.s11
|
DDI-DrugBank.d427.s11.p2
|
The purpose of this study was to evaluate the effect of sodium carboxymethylcellulose (NaCMC) and carboxymethylcellulose-cysteine (CMC-Cys) conjugates on the intestinal permeation of sodium fluorescein (NaFlu) and model peptide drugs, bacitracin and insulin.
|
sodium carboxymethylcellulose
|
NaCMC
|
NONE
|
11154900.xml
|
DDI-MedLine.d76.s1
|
DDI-MedLine.d76.s1.p0
|
Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.
|
niacinamide
|
propoxyphene
|
NONE
|
Carbamazepine_ddi.xml
|
DDI-DrugBank.d94.s4
|
DDI-DrugBank.d94.s4.p308
|
In general, most patients treated with dirithromycin who are receiving concomitant theophylline therapy may not require empiric adjustment of theophylline dosage or monitoring of theophylline plasma concentrations.
|
theophylline
|
theophylline
|
NONE
|
Dirithromycin_ddi.xml
|
DDI-DrugBank.d522.s13
|
DDI-DrugBank.d522.s13.p4
|
Studies have shown that lansoprazole does not have clinically significant interactions with other drugs metabolized by the cytochrome P450 system, such as warfarin, antipyrine, indomethacin, ibuprofen, phenytoin, propranolol, prednisone, diazepam, clarithromycin, or terfenadine in healthy subjects.
|
phenytoin
|
propranolol
|
NONE
|
Lansoprazole_ddi.xml
|
DDI-DrugBank.d431.s1
|
DDI-DrugBank.d431.s1.p40
|
Ketoconazole: Ketoconazole may inhibit both synthetic and catabolic enzymes of vitamin D.
|
Ketoconazole
|
vitamin D
|
MECHANISM
|
Calcitriol_ddi.xml
|
DDI-DrugBank.d384.s8
|
DDI-DrugBank.d384.s8.p2
|
Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.
|
desipramine
|
propafenone
|
NONE
|
Bupropion_ddi.xml
|
DDI-DrugBank.d5.s17
|
DDI-DrugBank.d5.s17.p68
|
Midazolam used at doses of 1.25 mg/kg and 2.5 mg/kg decreased the antinociceptive effect of morphine, metamizol (only in the tail-flick test) and indomethacin.
|
Midazolam
|
metamizol
|
EFFECT
|
11210678.xml
|
DDI-MedLine.d67.s7
|
DDI-MedLine.d67.s7.p1
|
Ketamine is clinically compatible with the commonly used general and local anesthetic agents when an adequate respiratory exchange is maintained.
|
Ketamine
|
anesthetic agents
|
NONE
|
Ketamine_ddi.xml
|
DDI-DrugBank.d518.s1
|
DDI-DrugBank.d518.s1.p0
|
We report the case of an adolescent with altered consciousness caused by carbamazepine overdose with a positive tricyclic antidepressant level to alert clinicians to the cross-reactivity of carbamazepine with a toxicology screen for tricyclic antidepressants.
|
carbamazepine
|
carbamazepine
|
NONE
|
11134454.xml
|
DDI-MedLine.d36.s2
|
DDI-MedLine.d36.s2.p1
|
Injection: Lorazepam injection, like other injectable benzodiazepines, produces depression of the central nervous system when administered with ethyl alcohol, phenothiazines, barbiturates, MAO inhibitors, and other antidepressants.When scopolamine is used concomitantly with injectable lorazepam, an increased incidence of sedation, hallucinations, and irrational behavior has been observed.
|
Lorazepam
|
benzodiazepines
|
NONE
|
Lorazepam_ddi.xml
|
DDI-DrugBank.d18.s1
|
DDI-DrugBank.d18.s1.p0
|
Acetazolamide reduces urinary excretion of quinidine and may enhance its effect.
|
Acetazolamide
|
quinidine
|
MECHANISM
|
Acetazolamide_ddi.xml
|
DDI-DrugBank.d368.s10
|
DDI-DrugBank.d368.s10.p0
|
Acetaminophen: A report of severe acetaminophen toxicity was reported in a patient receiving Isoniazid.
|
acetaminophen
|
Isoniazid
|
EFFECT
|
Isoniazid_ddi.xml
|
DDI-DrugBank.d187.s2
|
DDI-DrugBank.d187.s2.p2
|
Monitoring for amiodarone toxicity and serial measurement of amiodarone serum concentration during concomitant protease inhibitor therapy should be considered.
|
amiodarone
|
protease inhibitor
|
ADVISE
|
Amiodarone_ddi.xml
|
DDI-DrugBank.d143.s13
|
DDI-DrugBank.d143.s13.p2
|
The absorption of lymecycline may be affected by the simultaneous administration of indigestion remedies, iron or zinc supplements.
|
iron
|
zinc
|
NONE
|
Lymecycline_ddi.xml
|
DDI-DrugBank.d79.s0
|
DDI-DrugBank.d79.s0.p2
|
Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
|
anticoagulant
|
quinine
|
EFFECT
|
Anisindione_ddi.xml
|
DDI-DrugBank.d64.s87
|
DDI-DrugBank.d64.s87.p42
|
- a nonsteroidal anti-inflammatory drug (NSAID) such as ibuprofen (Motrin, Advil, Nuprin, others), ketoprofen (Orudis, Orudis KT, Oruvail), diclofenac (Voltaren, Cataflam), etodolac (Lodine), indomethacin (Indocin), nabumetone (Relafen), oxaprozin (Daypro), and naproxen (Anaprox, Naprosyn, Aleve);
|
Motrin
|
nabumetone
|
NONE
|
Glimepiride_ddi.xml
|
DDI-DrugBank.d521.s2
|
DDI-DrugBank.d521.s2.p82
|
Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
|
clofibrate
|
ranitidine
|
NONE
|
Anisindione_ddi.xml
|
DDI-DrugBank.d64.s87
|
DDI-DrugBank.d64.s87.p654
|
Interactions with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (eg, pentazocine, nalbuphine, butorphanol, dezocine and buprenorphine) should NOT be administered to a patient who has received or is receiving a course of therapy with a pure agonist opioid analgesic such as Levo-Dromoran.
|
Mixed Agonist/Antagonist Opioid Analgesics
|
Levo-Dromoran
|
NONE
|
Levorphanol_ddi.xml
|
DDI-DrugBank.d257.s6
|
DDI-DrugBank.d257.s6.p7
|
Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, perphenazine, phenylbutazone, phenytoin, salicylates, tamoxifen.
|
levothyroxine sodium
|
anabolic hormones
|
MECHANISM
|
Levothyroxine_ddi.xml
|
DDI-DrugBank.d411.s3
|
DDI-DrugBank.d411.s3.p1
|
Mineral oil interferes with the absorption of fat-soluble vitamins, including vitamin D preparations.
|
Mineral oil
|
fat-soluble vitamins
|
MECHANISM
|
Ergocalciferol_ddi.xml
|
DDI-DrugBank.d471.s0
|
DDI-DrugBank.d471.s0.p0
|
Digitalis: Immediate Release Capsules: Since there have been isolated reports of patients with elevated digoxin levels, and there is a possible interaction between digoxin and nifedipine, it is recommended that digoxin levels be monitored when initiating, adjusting, and discontinuing nifedipine to avoid possible over- or under-digitalization.
|
digoxin
|
nifedipine
|
ADVISE
|
Nifedipine_ddi.xml
|
DDI-DrugBank.d373.s2
|
DDI-DrugBank.d373.s2.p14
|
Central Nervous System Depressants: The concomitant use of DURAGESIC (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, hypnotics, tranquilizers (e.g., benzodiazepines), general anesthetics, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.
|
fentanyl
|
alcohol
|
EFFECT
|
Fentanyl_ddi.xml
|
DDI-DrugBank.d170.s5
|
DDI-DrugBank.d170.s5.p32
|
- Drugs whose efficacy is impaired by phenytoin include: anticoagulants, corticosteroids, coumarin, digitoxin, doxycycline, estrogens, furosemide, oral contraceptives, rifampin, quinidine, theophylline, vitamin D.
|
phenytoin
|
digitoxin
|
EFFECT
|
Fosphenytoin_ddi.xml
|
DDI-DrugBank.d40.s19
|
DDI-DrugBank.d40.s19.p3
|
However, iloprost has the potential to increase the hypotensive effect of vasodilators and antihypertensive agents.
|
iloprost
|
vasodilators
|
EFFECT
|
Iloprost_ddi.xml
|
DDI-DrugBank.d549.s1
|
DDI-DrugBank.d549.s1.p0
|
Do not mix TORADOL and morphine in the same syringe.
|
TORADOL
|
morphine
|
NONE
|
Ketorolac_ddi.xml
|
DDI-DrugBank.d3.s21
|
DDI-DrugBank.d3.s21.p0
|
Nabilone has been shown to have an additive CNS depressant effect when given with either diazepam, secobarbitone sodium, alcohol or codeine.
|
Nabilone
|
codeine
|
EFFECT
|
Nabilone_ddi.xml
|
DDI-DrugBank.d552.s1
|
DDI-DrugBank.d552.s1.p3
|
Platelet inhibitors: Drugs such as acetylsalicylic acid, dextran, phenylbutazone, ibuprofen, indomethacin, dipyridamole, hydroxychloroquine and others that interfere with platelet-aggregation reactions (the main hemostatic defense of heparinized patients) may induce bleeding and should be used with caution in patients receiving heparin sodium.
|
indomethacin
|
heparin sodium
|
EFFECT
|
Heparin_ddi.xml
|
DDI-DrugBank.d488.s2
|
DDI-DrugBank.d488.s2.p32
|
Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
|
influenza virus vaccine
|
anesthetics
|
NONE
|
Anisindione_ddi.xml
|
DDI-DrugBank.d64.s87
|
DDI-DrugBank.d64.s87.p1020
|
Amphotericin, Foscarnet, and Aminoglycosides: Drugs such as amphotericin, foscarnet, and aminoglycosides may increase the risk of developing peripheral neuropathy or other HIVID-associated adverse events by interfering with the renal clearance of zalcitabine (thereby raising systemic exposure).
|
amphotericin
|
HIVID
|
EFFECT
|
Zalcitabine_ddi.xml
|
DDI-DrugBank.d263.s18
|
DDI-DrugBank.d263.s18.p20
|
Initial doses of adrenergic agents, such as dopamine or epinephrine, should be reduced and titrated to achieve the desired response.
|
adrenergic agents
|
epinephrine
|
NONE
|
Linezolid_ddi.xml
|
DDI-DrugBank.d441.s4
|
DDI-DrugBank.d441.s4.p1
|
Because Anafranil is highly bound to serum protein, the administration of Anafranil to patients taking other drugs that are highly bound to protein (e.g., warfarin, digoxin) may cause an increase in plasma concentrations of these drugs, potentially resulting in adverse effects.
|
Anafranil
|
digoxin
|
MECHANISM
|
Clomipramine_ddi.xml
|
DDI-DrugBank.d238.s24
|
DDI-DrugBank.d238.s24.p4
|
Methadone: Coadministration of amprenavir and methadone can decrease plasma levels of methadone.
|
amprenavir
|
methadone
|
NONE
|
Amprenavir_ddi.xml
|
DDI-DrugBank.d437.s9
|
DDI-DrugBank.d437.s9.p4
|
Renal clearance measurements of PAH cannot be made with any significant accuracy in patients receiving sulfonamides, procaine, or thiazolesulfone.
|
PAH
|
procaine
|
EFFECT
|
Aminohippurate_ddi.xml
|
DDI-DrugBank.d416.s0
|
DDI-DrugBank.d416.s0.p1
|
In many of these cases, buprenorphine was misused by self-injection of crushed SUBUTEX tablets.
|
buprenorphine
|
SUBUTEX
|
NONE
|
Buprenorphine_ddi.xml
|
DDI-DrugBank.d380.s5
|
DDI-DrugBank.d380.s5.p0
|
Stavudine and Zidovudine Ribavirin can antagonize the in vitro antiviral activity of stavudine and zidovudine against HIV.
|
Ribavirin
|
zidovudine
|
EFFECT
|
Peginterferon alfa-2a_ddi.xml
|
DDI-DrugBank.d196.s6
|
DDI-DrugBank.d196.s6.p8
|
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.